Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(12):1046–1051. doi: 10.1111/j.1349-7006.2003.tb01399.x

β‐Catenin mutations and nuclear accumulation during progression of rat stomach adenocarcinomas

Tetsuya Tsukamoto 1, Masami Yamamoto 1, Naotaka Ogasawara 1, Toshikazu Ushijima 2, Tomoko Nomoto 2, Hirofumi Fujita 3,✉, Taijiro Matsushima 3, Koji Nozaki 1, Xueyuan Cao 1, Masae Tatematsu 1
PMCID: PMC11160191  PMID: 14662019

Abstract

Aberrant Wnt/β‐catenin signaling caused by mutations in exon 3 of the β‐catenin gene has been identified in a number of human malignancies, including stomach cancer. However, studies of mutation frequency have yielded conflicting results, and timing during progression remains largely unknown. In this study, we utilized an animal model to address this question. A total of 20 ACI male rats were treated with N‐methyl‐N′‐nitro‐N‐nitrosoguanidine (MNNG) in the drinking water and 22 induced differentiated adenocarcinomas were histopathologically and immunohistochemically evaluated for β‐catenin localization. Fourteen tumors (63.6%) that showed homogeneous low‐grade morphology, preserving cell polarity, were found to harbor β‐catenin protein on the cell membranes (M). Eight tumors exhibited regions of high‐grade morphology among areas with low‐grade morphology, and they were characterized by denser cell growth and loss of cell polarity. Among these 8 tumors, 4 (18.2%) showed cytoplasmic localization (C) of β‐catenin in small regions. The remaining 4 tumors (18.2%) contained more dysplastic regions that displayed nuclear (N) β‐catenin staining. Analysis of DNA obtained by microdissection demonstrated that all of 4 regions with C staining and 20 with M staining, as well as 17 samples of surrounding normal mucosa (S) had wild‐type β‐catenin. In contrast all of 3 regions with N staining featured mutations (3 of 3=100%; N vs. C, P<0.05; N vs. M and N vs. S, P<0.001, Fisher's exact test) in exon 3, at glycine 34, threonine 41, and serine 45, which affected phosphorylation sites. In conclusion, β‐catenin mutations appear to be associated with the late progression stage of adenocarcinoma development in rat stomach carcinogenesis, in contrast to the case of colorectal cancers, in which mutations appear to occur in the early stages.

References

  • 1. El‐Rifai W, Powell SM. Molecular biology of gastric cancer. Semin Radiat Oncol 2002; 12: 128–40. [DOI] [PubMed] [Google Scholar]
  • 2. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 2000; 910: 121–37; discussion 37–9. [DOI] [PubMed] [Google Scholar]
  • 3. Strathdee G. Epigenetic versus genetic alterations in the inactivation of E‐cadherin. Semin Cancer Biol 2002; 12: 373–9. [DOI] [PubMed] [Google Scholar]
  • 4. Yokozaki H, Yasui W, Tahara E. Genetic and epigenetic changes in stomach cancer. Int Rev Cytol 2001; 204: 49–95. [DOI] [PubMed] [Google Scholar]
  • 5. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837–51. [PubMed] [Google Scholar]
  • 6. Candidus S, Bischoff P, Becker KF, Hofler H. No evidence for mutations in the alpha‐ and beta‐catenin genes in human gastric and breast carcinomas. Cancer Res 1996; 56: 49–52. [PubMed] [Google Scholar]
  • 7. Sasaki Y, Morimoto I, Kusano M, Hosokawa M, Itoh F, Yanagihara K, Imai K, Tokino T. Mutational analysis of the beta‐catenin gene in gastric carcinomas. Tumour Biol 2001; 22: 123–30. [DOI] [PubMed] [Google Scholar]
  • 8. Tong JH, To KF, Ng EK, Lau JY, Lee TL, Lo KW, Leung WK, Tang NL, Chan FK, Sung JJ, Chung SC. Somatic beta‐catenin mutation in gastric carcinoma‐an infrequent event that is not specific for microsatellite instability. Cancer Lett 2001; 163: 125–30. [DOI] [PubMed] [Google Scholar]
  • 9. Woo DK, Kim HS, Lee HS, Kang YH, Yang HK, Kim WH. Altered expression and mutation of beta‐catenin gene in gastric carcinomas and cell lines. Int J Cancer 2001; 95: 108–13. [DOI] [PubMed] [Google Scholar]
  • 10. Ebert MP, Fei G, Kahmann S, Muller O, Yu J, Sung JJ, Malfertheiner P. Increased beta‐catenin mRNA levels and mutational alterations of the APC and beta‐catenin gene are present in intestinal‐type gastric cancer. Carcinogenesis 2002; 23: 87–91. [DOI] [PubMed] [Google Scholar]
  • 11. Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio‐Preiser C, Groden J, Lowy AM. Beta‐catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res 2002; 62: 3503–6. [PubMed] [Google Scholar]
  • 12. Ohene‐Abuakwa Y, Noda M, Perenyi M, Kobayashi N, Kashima K, Hattori T, Pignatelli M. Expression of the E‐cadherin/catenin (alpha‐, beta‐, and gamma‐) complex correlates with the macroscopic appearance of early gastric cancer. J Pathol 2000; 192: 433–9. [DOI] [PubMed] [Google Scholar]
  • 13. Miyazawa K, Iwaya K, Kuroda M, Harada M, Serizawa H, Koyanagi Y, Sato Y, Mizokami Y, Matsuoka T, Mukai K. Nuclear accumulation of beta‐catenin in intestinal‐type gastric carcinoma: correlation with early tumor invasion. Virchows Arch 2000; 437: 508–13. [DOI] [PubMed] [Google Scholar]
  • 14. Sugimura T, Fujimura S. Tumour production in glandular stomach of rat by N‐methyl‐N'‐nitro‐N‐nitrosoguanidine. Nature 1967; 216: 943–4. 6074981 [Google Scholar]
  • 15. Ohgaki H, Sugimura T. Experimental gastric cancer. In: Sugimura T, Sasako M, editors. Gastric cancer. New York : Oxford University Press; 1997. p. 73–86. [Google Scholar]
  • 16. Tatematsu M, Takahashi M, Fukushima S, Hananouchi M, Shirai T. Effects in rats of sodium chloride on experimental gastric cancers induced by N‐me‐thyl‐N‐nitro‐N‐nitrosoguanidine or 4‐nitroquinoline‐1‐oxide. J Natl Cancer Inst 1975; 55: 101–6. [DOI] [PubMed] [Google Scholar]
  • 17. Tatematsu M, Furihata C, Hirose M, Shirai T, Ito N. Changes in pepsinogen isozymes in stomach cancers induced in Wistar rats by N‐methyl‐N'‐nitro‐N‐nitrosoguanidine and in transplantable gastric carcinoma (SG2B). J Natl Cancer Inst 1977; 58: 1709–16. [DOI] [PubMed] [Google Scholar]
  • 18. Tatematsu M, Katsuyama T, Fukushima S, Takahashi M, Shirai T, Ito N, Nasu T. Mucin histochemistry by paradoxical concanavalin A staining in experimental gastric cancers induced in Wistar rats by N‐methyl‐N‐nitro‐N‐nitrosoguanidine or 4‐nitroquinoline 1‐oxide. J Natl Cancer Inst 1980; 64: 835–43. [PubMed] [Google Scholar]
  • 19. Ohgaki H, Kawachi T, Matsukura N, Morino K, Miyamoto M, Sugimura T. Genetic control of susceptibility of rats to gastric carcinoma. Cancer Res 1983; 43: 3663–7. [PubMed] [Google Scholar]
  • 20. Tatematsu M, Furihata C, Katsuyama T, Mera Y, Inoue T, Matsushima T, Ito N. Immunohistochemical demonstration of pyloric gland‐type cells with low‐pepsinogen isozyme 1 in preneoplastic and neoplastic tissues of rat stomachs treated with N‐methyl‐N'‐nitro‐N‐nitrosoguanidine. J Natl Cancer Inst 1987; 78: 771–7. [PubMed] [Google Scholar]
  • 21. Hirayama Y, Wakazono K, Yamamoto M, Kitano M, Tatematsu M, Nagao M, Sugimura T, Ushijima T. Rare mutations of p53, Ki‐ras, and beta‐catenin genes and absence of K‐sam and c‐erbB‐2 amplification in N‐methyl‐N'‐nitro‐N‐nitrosoguanidine‐induced rat stomach cancers. Mol Carcinog 1999; 25: 42–7. [DOI] [PubMed] [Google Scholar]
  • 22. Yamamoto M, Tsukamoto T, Sakai H, Shirai N, Ohgaki H, Furihata C, Done‐hower LA, Yoshida K, Tatematsu M. p53 knockout mice (−/−) are more susceptible than (+/−) or (+/+) mice to N‐methyl‐N‐nitrosourea stomach carcinogenesis. Carcinogenesis 2000; 21: 1891–7. [DOI] [PubMed] [Google Scholar]
  • 23. Tsukamoto T, Tanaka H, Fukami H, Inoue M, Takahashi M, Wakabayashi K, Tatematsu M. More frequent β‐catenin gene mutations in adenomas than in aberrant crypt foci or adenocarcinomas in the large intestines of 2‐amino‐1‐methyl‐6‐phenylimidazo[4,5‐b]pyridine (PhIP)‐treated rats. Jpn J Cancer Res 2000; 91: 792–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ, Lee JY. Frequent somatic mutations of the beta‐catenin gene in intestinal‐type gastric cancer. Cancer Res 1999; 59: 4257–60. [PubMed] [Google Scholar]
  • 25. Koesters R, Hans MA, Benner A, Prosst R, Boehm J, Gahlen J, Doeberitz MK. Predominant mutation of codon 41 of the beta‐catenin proto‐oncogene in rat colon tumors induced by 1,2‐dimethylhydrazine using a complete carcinogenic protocol. Carcinogenesis 2001; 22: 1885–90. [DOI] [PubMed] [Google Scholar]
  • 26. Takahashi M, Fukuda K, Sugimura T, Wakabayashi K. Beta‐catenin is frequently mutated and demonstrates altered cellular location in azoxymethane‐induced rat colon tumors. Cancer Res 1998; 58: 42–6. [PubMed] [Google Scholar]
  • 27. Dashwood RH, Suzui M, Nakagama H, Sugimura T, Nagao M. High frequency of beta‐catenin (ctnnb1) mutations in the colon tumors induced by two heterocyclic amines in the F344 rat. Cancer Res 1998; 58: 1127–9. [PubMed] [Google Scholar]
  • 28. Blum CA, Xu M, Orner GA, Fong AT, Bailey GS, Stoner GD, Horio DT, Dashwood RH. Beta‐catenin mutation in rat colon tumors initiated by 1,2‐dimethylhydrazine and 2‐amino‐3‐methylimidazo[4,5‐f]quinoline, and the effect of post‐initiation treatment with chlorophyllin and indole‐3‐carbinol. Carcinogenesis 2001; 22: 315–20. [DOI] [PubMed] [Google Scholar]
  • 29. Suzui M, Ushijima T, Dashwood RH, Yoshimi N, Sugimura T, Mori H, Nagao M. Frequent mutations of the rat beta‐catenin gene in colon cancers induced by methylazoxymethanol acetate plus 1‐hydroxyanthraquinone. Mol Carcinog 1999; 24: 232–7. [DOI] [PubMed] [Google Scholar]
  • 30. Suzui M, Sugie S, Mori H, Okuno M, Tanaka T, Moriwaki H. Different mutation status of the beta‐catenin gene in carcinogen‐induced colon, brain, and oral tumors in rats. Mol Carcinog 2001; 32: 206–12. [DOI] [PubMed] [Google Scholar]
  • 31. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF. Beta‐catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 1997; 94: 10330–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta‐catenin‐Tcf signaling in colon cancer by mutations in beta‐catenin or APC. Science 1997; 275: 1787–90. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES